Background: Information about the timing involved in various stages of making new drugs
available to Canadians is important for understanding how a national pharmacare plan will …

Individuals who rely on public health payers to access new medicines can access fewer
innovative medicines and must wait longer in Canada compared to major markets around …

Objectives In addition to Canadian Drug Review (CDR), an independent, province-driven
mechanism is now in place known as Pan Canadian Pricing Alliance (pCPA). The purpose …

Objectives To examine whether there has been a change in the number of therapeutically
important new medicines not being introduced into the Canadian market in light of the …

Background. To save costs, the Australian Government recently deferred approval of seven
new medicines recommended by the Pharmaceutical Benefits Advisory Committee (PBAC) …

The Canadian federal government has proposed significant revisions to the way its patented
medicines price regulator assesses the excessiveness of medication prices that are to take …

Canada has experienced much uncertainty about the federal government's intention to
regulate lower ceiling prices for patented medicines during the past seven years. This …

Introduction Studies of the delay between when companies file a New Drug Submission
(NDS) and when drugs reach Canadian patients typically focus on the time in the regulatory …

Objectives This study was conducted to determine whether establishment of the pan-
Canadian Pharmaceutical Alliance (pCPA) was associated with significant changes in drug …

Background: Canada's Common Drug Review was implemented to provide publicly funded
drug plans (provincial and federal) with a transparent, rigorous and consistent approach for …